The George Institute For Global Health
Global
United Kingdom
India
China
Australia

Home

Found 329 results
Filters: Author is Vlado Perkovic
2018
Wong M, Heerspink H, Perkovic V. ACCORDION: Ensuring That We Hear the Music Clearly. Clinical journal of the American Society of Nephrology : CJASN. 2018;13:1621 - 1623. doi:10.2215/CJN.11370918.
Pecoits-Filho R, Perkovic V. Are SGLT2 Inhibitors Ready for Prime Time for CKD?. Clin J Am Soc Nephrol. 2018;13(2):318-320. doi:10.2215/CJN.07680717.
Mohammedi K, Chalmers J, Herrington W, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018;8(1):7. doi:10.1038/s41387-017-0012-y.
Heerspink H, Andress D, Bakris G, et al. Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism. 2018;20:1829 - 1835. doi:10.1111/dom.13315.
Heerspink HJL, Andress DL, Bakris G, et al. Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. Diabetes Obes Metab. 2018. doi:10.1111/dom.13315.
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018. doi:10.1161/CIRCULATIONAHA.118.034222.
Perkovic V, Neuen B, Ohkuma T, et al. CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Spring Clinical Meeting of the National-Kidney Foundation (NKD). 2018:574 - 574.
Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018. doi:10.1016/S2213-8587(18)30141-4.
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-334. doi:10.1161/CIRCULATIONAHA.117.032038.
Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program. Circulation. 2018. doi:10.1161/CIRCULATIONAHA.118.035901.
John O, Ohkuma T, Zoungas S, et al. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care. 2018;41(1):163-170. doi:10.2337/dc17-1467.
Rosenstock J, Perkovic V, Johansen O, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2018. doi:10.1001/jama.2018.18269.
Rådholm K, Wu J, Wong M, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice. 2018;140:118 - 128. doi:10.1016/j.diabres.2018.03.027.
De Z, Renfurm R, Bakris G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology. 2018;6:925 - 933. doi:10.1016/S2213-8587(18)30289-4.
Smyth B, Chan C, Grieve S, et al. Factors Associated With Regression Of Left Ventricular Mass Index In The Active Dialysis Trial. In: NEPHROLOGY; 2018:28 - 28. Available at: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a.
Okpechi I, Alrukhaimi M, Ashuntantang G, et al. Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. Kidney International Supplements. 2018;8:27 - 29. doi:10.1016/j.kisu.2017.10.012.
Wong M, Jardine M, Perkovic V. Glucose lowering and the kidney: are all drug classes equal?. The lancet. Diabetes & endocrinology. 2018;6:835 - 837. doi:10.1016/S2213-8587(18)30291-2.
Smyth B, Howard K, Zuo L, et al. Impact Of Extended Hours Dialysis On Utility-Based Quality Of Life: Results From The Active Dialysis Trial. In: NEPHROLOGY; 2018:11 - 12. Available at: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a.
Tong A, Manns B, Wang A, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney International. 2018. doi:10.1016/j.kint.2018.08.018.
Matthews D, Perkovic V, Mahaffey K. Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". Circulation. 2018;138:660 - 661. doi:10.1161/CIRCULATIONAHA.118.035717.
Heerspink H, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes, Obesity and Metabolism. 2018;20:14 - 18. doi:10.1111/dom.13417.
Heerspink HJL, Andress DL, Bakris G, et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018;20:1369 - 1376. doi:10.1111/dom.13245.
Rosenstock J, Perkovic V, Alexander J, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): A randomized, double-blind, placebo-control. Cardiovascular Diabetology. 2018;17. doi:10.1186/s12933-018-0682-3.
Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio. Cardiovasc Diabetol. 2018;17(1):39. doi:10.1186/s12933-018-0682-3.
Neuen B, Perkovic V. Reducing cardiovascular risk in people with diabetes and kidney disease. The Medical journal of Australia. 2018;209:438 - 439. doi:10.5694/mja18.00929.

Pages